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ABSTRACT 
Objective: Itopride Hydrochloride (ITO) is a prokinetic agent commonly used for the treatment of gastroesophageal reflux disease. It activates GI 
propulsive motility due to its dopamine D2 antagonizing activity and acetylcholinesterase inhibitory activity. The present work deals with 
application of sintering technique to matrix tablets of itopride hydrochloride to achieve sustained release using hydrophobic polymers 
Methods: Eudragit L-100 and carnauba wax were used in combination to achieve sustained release. A 32 
Results: The results of a 3
factorial design was used to study the 
effect of sintering and various ratios of Eudragit and carnauba wax on percent drug release at 10 h, contact angle, and porosity. The tablets were 
also evaluated in terms of tensile strength, in-vitro dissolution and pharmacokinetic studies. 
2 full factorial design revealed that sintering caused decrease in drug release as compared to unsintered tablets. The 
concentration ratio of Eudragit L-100 and carnauba wax polymers also significantly affected the release profile. Carnauba wax maintained the 
integrity of the matrix, whereas Eudragit L-100 slowly eroded in the matrix as the drug was released. Thus, the area-to-volume ratio of the tablet 
remained constant over the duration of the drug release. The optimized formulation followed first order release kinetics with the diffusion-erosion 
mechanism. In vivo studies revealed higher Tmax of matrix tablet compared to a plain drug which is suggestive of slower absorption. However, the 
AUC0-10 h
Conclusion: Matrix tablets of Itopride hydrochloride can be formulated using the sintering technique to achieve sustained drug release along with 
increased bioavailability. 
 of the optimized formula and plain drug was found to be 1.561 h. µg/ml and 0.481 h. µg/ml respectively. 
Keywords: Sintering, Matrix tablets, Eudragit L-100, Carnauba wax. 
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INTRODUCTION 
Oral route is one of the most convenient routes for drug 
administration among all the routes [nasal, ophthalmic, rectal, 
transdermal and parenteral routes] that have been explored for 
systemic delivery of drugs. Sustained release tablets are commonly 
taken only once or twice daily, compared with conventional forms 
that may have to be taken three or four times daily to achieve the 
equivalent therapeutic effect. The advantage of administering a 
single dose of a drug that is released over an extended period of time 
to maintain a near-constant or consistent blood level of a drug often 
translates into better patient compliance, as well as enhanced the 
clinical efficacy of the drug for its intended use [1, 2]. 
The sustained drug delivery can be achieved by matrix tablet 
wherein a solid drug is dispersed in an insoluble matrix. Drug in the 
outside layer exposed to the bathing solution is dissolved first and 
then diffuses out of the matrix. The rate of release of drug is 
dependent on the rate of drug diffusion and not on the rate of solid 
dissolution. The matrix tablets can be prepared by wet granulation 
method. Wet granulation method has several advantages over dry 
granulation method like better flow properties of granules and less 
generation of dust while mixing [1-5]. Thermal sintering involves 
the heating of a compact at a temperature below the melting point of 
the solid constituents in a controlled environment under 
atmospheric pressure. It is a simple, effective and economical 
process to obtain sustained release of drug from the tablet with 
comparatively less quantity of polymer [6]. The sintering technique 
is used extensively for sustained release in various drug i.e. 
Propranolol hydrochloride, Diltiazem Hydrochloride and Ketorolac 
tromethamine [7-9]. 
ITO a BCS class III drug, it is freely soluble in water with Log p value 
of 2.32 and 60% bioavailability. ITO (50 mg) is given thrice a day 
along with proton pump inhibitors like omeprazole, esomeprazole, 
and pantoprazole. ITO is used for treatment of various digestive 
conditions like heartburn, regurgitation, epigastria pain, esophagitis 
etc. These conditions include GERD, non ulcer dyspepsia, chronic 
gastritis and a very important complication seen in diabetics where in 
the gastric emptying is markedly reduced i.e. diabetic gastro paresis. 
By developing the sustained release formulation of ITO, the frequency 
of drug administration can be reduced to once a day and one can 
achieve better therapeutic response [9-11]. Hydrophobic polymer 
matrix systems are extensively used because of their flexibility to 
obtain a desirable drug release profile, cost effectiveness and broad 
regulatory acceptance. In present study Eudragit L-100 (EL-100) and 
carnauba wax (C. wax) were used as matrix polymers and sustained 
release tablets were prepared by combining matrixing and sintering 
techniques to modulate the release profile of the drug. 
MATERIALS AND METHODS 
Materials  
Itopride Hydrochloride (ITO) was obtained as a gift sample from 
Ami Life Sciences Pvt. Ltd. Baroda Gujarat, India. Xanthan gum was 
obtained from Hi Media Laboratories Pvt. Ltd. Mumbai, Eudragit L-
100 was obtained from Roehm Pharma Polymers, Carnauba wax 
was obtained from Vishal Chem Mumbai, Microcrystalline cellulose, 
Magnesium stearate and Talc was obtained from M/S Lobachemie 
ltd, Mumbai. 
Preliminary studies  
Matrix granules of ITO were prepared by wet granulation method. 
Various polymers such as EL-100, C. wax, Xanthan gum (XG) and 
microcrystalline cellulose (MCC) were investigated as singly and in 
combination in different ratios. Polyvinyl pyrrolidone (PVP) 
dissolved in hydroalcoholic solvent (70% v/v) was used as a binder 
to prepare granules, which were passed through sieve no. 16. The 
granules were dried at 50 °C for 4h. The dried granules were 
screened through sieve no. 16 and stored at ambient temperature 
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for further studies. The granules were mixed with of magnesium 
stearate and talc in require quantity and compressed using rotary 
tablet compression machine (12 stations, Mini press–II MT, Rimek, 
India), using 12.5 mm diameter flat punches. The tablets were 
placed on aluminum foil and subjected to thermal treatment at 60 °, 
70 ° and 80 ° C for 1, 2 and 3 h in hot air oven (Biomedica lab ovens). 
Drug-Excipients compatibility study 
ITO alone and in mixture with other excipients was subjected to 
FTIR and DSC studies to check the possibility of any interaction with 
each other. One month compatibility study was done on physical 
mixture at 40 °C/75% RH. Binary mixtures of ITO and all excipients 
in 1:1 ratio were subjected to specified conditions, IR spectra of a 
physical mixture of ITO and excipients were recorded to study the 
interaction of drug and polymer after a month. FTIR spectrum of 
resultant product was taken and compared with the spectrum of ITO. 
The Differential scanning calorimetric thermograms of the pure 
drug, polymer and drug and polymer physical mixtures were 
recorded using differential scanning calorimeter (DSC823e Mettler 
Toledo, Japan). Approximately 2 to 5 mg of each sample was heated in 
a closed pierced aluminum pan from 30 °to 300 °C at a heating rate of 
10 °C/min under a stream of nitrogen at a flow rate of 50 ml/min [12]. 
Experimental design 
The optimization of sustained release formulation of ITO was done 
by using Design expert software (Design Expert trial version 7.0.3). 
Based on the results of preliminary studies combination of EL-100 
and C. wax were used for further optimization studies. A 32 full 
factorial design was used where independent variables were ratio of 
EL-100 and C. wax (X1) as 1:1, 2:1 and 1:2 and sintering time of 1,2 
and 3h at 80°C (X2) at three levels. The responses selected were 
percentage release after 10 h (Y1), contact angle (Y2) and porosity 
(Y3
Evaluation of granules 
). All other formulation and processing variables were kept 
invariant throughout the study. So a total of 9 formulations (F1-F9) 
were prepared. 
The flow properties of granules were characterized in terms of angle 
of repose, Carr index and Hausner's ratio. The bulk density and 
tapped density were determined and from this data Carr's index and 
Hausner's ratio were calculated [13, 14]. Tablets from all the 
formulations were evaluated for various properties like hardness 
(Monsanto hardness tester), thickness (Vernier caliper), Friability 
and weight variation, drug content [13, 14]. 
Evaluation of matrix tablets 
Contact angle measurement 
The contact angle (θ) between purified water and tablet surfaces 
was determined by placing a 10 µl of water on surface of tablet using 
micropipette. Photographs of the drop in contact with water were 
taken. The drop was photographed after 10 sec. It was carefully 
superimposed on tracing paper and the contact angle was measured. 
Amaranth red was added to the water to ensure proper visibility of 
the drop [7]. 
Porosity 
The true density was determined by helium pycnometry (Pycno 30, 
Smart Instruments, Mumbai, India) at 25±2 °C/40±5% RH. This 
method measures the volume of gas (Helium) displaced by a known 
mass of tablet, and gives the true density of the material. The sample 
must be completely dried. The porosity, ε, of the tablets was 
calculated by Eq. 1, 
ε =  1–
ρc
ρt
… … … Eq. 1 
Where ρc is the density of the tablet calculated from the weight and 
volume of the resulting tablet. Ρt
Tablet Tensile Strength 
 is the true density of powder [15, 16]. 
The breaking force of the tablets was measured using a tablet 
hardness tester (Monsanto hardness tester). Tablet dimensions 
were measured using a digital caliper (Vernier caliper). Tensile 
strength was calculated using Eq. 2 to eliminate the undesirable 




… … … Eq. 2 
Where σ is the tensile strength (MPa), F is the observed breaking 
force (N), d is the diameter (mm), and t is the thickness of the 
compact (mm) [15, 16]. 
In vitro dissolution test 
Dissolution studies were carried out in USP type II (paddle type) 
dissolution apparatus (TDT-08L, Electrolab) in 900 ml medium at 
37±0.5˚C at a rotation speed of 50 rpm. The dissolution medium 
comprised of 750 ml of 0.1 N HCl for first 2 h followed by 150 ml of a 
0.2 M solution of trisodium phosphate dodecahydrateto adjust the 
pH to 6.8 for next 10 h. The pH was adjusted with 2M hydrochloric 
acid or 2M sodium hydroxide to a pH of 6.8±0.05. The drug release 
at different time intervals was measured by a UV-visible 
spectrophotometer (Lab india3000, India) at 247 nm (in 0.1N HCl) 
and 258 nm (in pH 6.8). The release studies were conducted in 
triplicate (6 tablets in each set) and the mean values were plotted 
versus time with standard deviation (SD) of less than 3, indicating 
the reproducibility of the results [17]. Kinetics of drug release from 
the sustained release matrix tablets was studied using DDsolver 
Disso 1 software and mathematical models such as zero-order, first-
order, Higuchi, Hixon-crowell, Korsmeyer-peppas models were 
evaluated by the model-dependent (curve fitting) method. 
In-vivo pharmacokinetic studies 
Male Wistar rats, weighing 230–330 g, were fasted for 24 h with free 
access to water. The rats were divided into three groups of six rats 
each, viz., first group served as negative control, second group was 
administered pure ITO solution and third group was administered 
optimized formulation. Tablets were given orally to rats in a dose 
equivalent to 5 mg/kg of drug [18]. The rats were anaesthetized 
with the help of ether, and the retro-orbital method was used to 
removal of blood samples. Blood samples were withdrawn from the 
retro-orbital vein at intervals of 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 h and 
analyzed by bioanalytical HPTLC method using a mixture of n-
butanol: toluene: ammonia (8.5:0.5:1 v/v) as mobile phase [19] and 
detected at λ max 
Stability studies  
of 258 nm [20]. A simple protein precipitation 
method was employed for extraction of the drug from rat plasma 
using 10% perchloric acid. The protocol for the animal experiment 
was approved by the Institutional Animal Ethical Committee (Ref no. 
AISSMS/IAEC/14-15/01-21). 
The formulations were subjected to the accelerated stability studies 
(40° C±2° C/75%RH±5%RH). Samples were withdrawn periodically 
at 0, 15, 30 d and evaluated for drug content, weight of tablet and in 
vitro dissolution studies. 
RESULTS AND DISCUSSION 
Preliminary studies  
From the dissolution study of all trial batches, it was evident that 
release from the matrix is largely dependent on the polymer, drug 
diffusion and matrix erosion. The drug release study was carried out 
up to 10 h. The percentage drug release from batch A1 (ITO: EL-100 
1:1 ratio), A2 (ITO: C. wax 1:1 ratio), A3 (ITO: XG1:1 ratio) and A4 
(ITO: MCC 1:1 ratio) was found to be 92.62(8 h), 91.87(8 h), 91.21(8 
h) and 99.86 (4 h) % respectively. After carrying out sintering of 
same batches, drug release was found to be 76.45, 80.03, 83.55% in 
10 h and 99.7% in 6 h respectively. Batches A5 (ITO: EL-100), A6 
(ITO: C. wax), A7 (ITO: XG) with drug polymer ratio of 1:2, exhibited 
comparatively lesser amounts of drug release than A1, A2 and A3 of 
98.01, 99.13 and 99.72% in 10 h respectively. This could be attributed 
to the fact that, large concentration of EL-100 polymer induces the 
formation of strong films resistant to gastric fluid that slowed down 
the rate of water diffusion into the tablet matrix. This may result in the 
retardation of drug release. This polymer after forming salts dissolves 
above pH 5.5 and disperses in water, forming latex [21]. 
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There was no significant decrease in release drug values in batches 
A5, A6 and A7 despite using double the concentration of polymers 
than A1, A2 and A3 (1:1). Hence, a combination of both the polymers 
were selected in the third trial batch i.e. A8 and A9 with both the 
batches having drug and polymers ratio of 1:1. The batch A8 had 
polymers (EL-100: XG) in the ratio 2:1. Due to combination of a 
hydrophilic (XG) and hydrophobic polymer (EL-100) the release 
profiles of these batches changed accordingly. XG due to its tendency 
to swell in aqueous systems retarded the release profile [14]. The 
percentage drug release from batch A8 was 99.86 % in 10 h. After 
sintering drug release of 97.45 % was observed. This indicated that 
sintering did not result in a significant change in percent release. 
Since melting point of XG is high (270 °C), its effective sintering 
could not be carried out. Hence XG was not selected for further 
study. Therefore C. wax (melting point 80-86°C) was selected for A9 
batch and further combinations were made of C. wax with EL-100. 
The batch A9 had polymers (EL-100, C. wax) in the ratio 2:1. The 
percentage drug release from batch A9 was found to be 92.48 % and 
after the sintering at 80 °C for 3h the percentage drug release was 
found to be 74.75%. Since a remarkable change in percent release 
was observed after sintering, combination of EL-100 and C. wax was 
investigated further. 
  
Table 1: Preliminary batches of ITO matrix tablet 
Formulation ITO EL100 C. wax XG MCC PVP Mg. stearate Talc 
A1 135 135 - - - 80 25 25 
A2 135 - 135 - - 80 25 25 
A3 135 - - 135 - 80 25 25 
A4 135 - - - 135 80 25 25 
A5 135 270 - - - 80 25 25 
A6 135 - 270 - - 80 25 25 
A7 135 - - 270 - 80 25 25 
A8 135 90 - 45 - 80 25 25 
A9 135 90 45 - - 80 25 25 
 
Drug excipients compatibility studies 
The samples were checked for physical changes such as 
discoloration and odour no changes were observed during 
compatibility study. 
Fourier–transform infrared spectroscopy 
The IR absorbance spectrum of ITO was recorded using Fourier–
transform infrared spectrometer (460 Plus, Jasco) over a range of 
400 to 4000 cm-1 at a resolution of 2 cm-1. The major drug peaks 
(functional group) at 3223, 3286 cm-1[N-H asymmetric and 
symmetric structure respectively]; 1650 cm-1[C=O bending]; 1509 
cm-1[C=C aromatic structure]; 2968, 2622 cm-1 [C-H structure of 
aromatic and C-H structure of CH3 
Differential scanning calorimetry 
group respectively] were seen in 
subsequent spectra. The characteristic peaks of ITO were not altered 
and hence it was concluded that no any significant interaction 
between ITO and selected excipients was evident. Insignificant 
shifting of spectra or reduction in peak intensity was evident. 
The thermogram of ITO shows a sharp melting endotherm at 
194.71°C (fig. 1). The thermogram of a binary mixture of ITO with C. 
wax showed two endothermic peaks corresponding to the melting 
point of C. wax at 83.58 °C and of the drug. Similarly the drug 
endotherm was evident in thermogram of its binary mixture with 
EL-100. These thermograms indicate that drug and polymers were 
compatible with each other and also point to the fact that drug is not 
molecularly dispersed in the polymer matrix. 
 
 
Fig. 1: DSC thermogram of drug excipients compatibility studies a) Pure drug b) drug+C. wax c) drug+EL-100 
 
Evaluation of granules and matrix tablets 
Various batches given by study design were evaluated. The granules 
prepared for compression of matrix tablets were evaluated for their 
flow properties. The bulk density was within the range of 0.411 to 
0.453 gm/cm3. Tapped density ranged between 0.502-0.598 
gm/cm3. This indicates good packing capacity of granules. Angle of 
repose was within the range of 22.98 to 25.12 i.e. granules were of 
good flow properties. Compressibility index was found to be 13.21-
24.05 showing good flow characteristics. Hausner ratio ranged from 
1.152-1.454 which confirmed above findings [15]. All the tablets 
showed elegant appearance. The hardness of the tablets of all 
formulations was within the range of 5.03 to 5.7 kg/cm2, indicating 
satisfactory mechanical strength. The particle loss in the friability 
test was below 1% for all the formulations, which is an indication of 
good mechanical resistance of the tablets [18]. The variation in 
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weight was within the range of±7.5% complying with Pharma-
copoeia specifications [18]. The percentage of ITO in all formulations 
was in the range OF 97.92-99.46% indicating content uniformity 
was within the limits (±10%). 
 
 
Fig. 2: Tensile strength for matrix tablets of batches F1-F9 
 
Tensile strength 
Tensile strength can be used as a measure of the inherent strength of 
compacted material and the ability of particle binding. The tensile 
strength of all tablet formulations was within the range of 0.0902 to 
0.1022 MPa (fig. 2) indicating satisfactory mechanical strength. 
Sintering caused increased binding of particles in matrix tablets, 
which resulted in increased tortuosity and decreases porosity. An 
increase in tensile strength resulted in decreased drug release rate. 
The tensile strength was found to increase with increasing in 
polymer concentration ratio [22, 23]. 
Factorial design 
A 32 factorial design was applied to study the effect of sintering (X2) 
on the drug release from matrix tablet of ITO with different ratios of 
EL-100 and C. wax (X1). The dependent variables chosen were 
amount of drug release after 10 h (%rel10 h
Table 2: Reponses of batches in 3
), contact angle ( °) and 
porosity (table 2). A statistical model incorporating interactive and 
polynomial terms was used to evaluate the responses. Analysis of 
experimental results was carried out by using Design Expert V 9.1 
software. Quadratic model was suggested to run the design. F-
values, P-value and model F-value for percent drug release at 10 h, 
contact angle and porosity were obtained from ANOVA. The 
selection of model and polynomial equations are listed in (table 3). 
2
Batch code 
 factorial designs 
Coded value % Contact angle ( °) rel10 h Porosity  
X X1 2 
F1 1:2 (-1) 1h (-1) 91.41 43 0.1507 
F2 1:2 (-1) 2h (0) 88.38 53 0.1424 
F3 1:2 (-1) 3h (+1) 81.79 64 0.1628 
F4 1:1 (0) 1h (-1) 91.48 50 0.1652 
F5 1:1 (0) 2h (0) 86.65 58 0.1288 
F6 1:1 (0) 3h (+1) 78.78 66 0.1452 
F7 2:1 (+1) 1h (-1) 91.63 55 0.1916 
F8 2:1 (+1) 2h (0) 85.53 61 0.1500 
F9 2:1 (+1) 3h (+1) 75.77 67 0.1479 
 
Table 3: Summary of results of regression analysis 
Model % Contact angle rel10 h Porosity 
coefficient p-value coefficient p-value coefficient p-value 
Intercept 86.82 0.0001 57.89 0.0001 0.23084 0.0105 
X -1.37 1 0.0003 3.83 0.0001 -2.01101 0.0486 
X -6.30 2 0.0001 8.17 0.0001 -0.047408 0.0159 
X1X -1.66 2 0.0003 -2.25 0.0004 -8.37084 0.0072 
X1 0.046 2 0.7217 -0.83 0.0190 4.0208 0.0341 
X2 -1.78 2 0.0006 0.17 0.4228 0.020167 0.0068 
R 0.9997 2 0.9996 0.9784 
 
In vitro dissolution study 
From the dissolution study of batches F1 to F9, it can be concluded 
that release from the matrix is largely dependent on the polymer 
swelling, drug diffusion and matrix erosion. The drug release study 
was carried out up to 10 h. The percentage drug release from batch F1 
to F9 ranged from 75.77 to 91.63%. The tablets containing a higher 
concentration of EL-100 and lower concentration of C. wax showing 
retardation in drug release. The concentration of EL-100 increased 
from F1 to F9 batches whereas C. wax decreased. C. wax is partially 
soluble at all pHs [24, 25] whereas EL-100 undergoes dissolution in 
pH range of above 5.5 [26]. This causes slow erosion of the polymer 
matrix providing micro channels through which the drug diffuses 
out. Additionally sintering causes the wax to melt, redistribute and 
coat drug and excipients particles, thus causing retardation of drug 
release [27]. The drug release from these polymer-wax matrices is 
described by a combination diffusion/erosion mechanism [28]. 
Dissolution profiles for all batches were shown in (fig. 3).  
 
Fig. 3: In vitro drug release profiles for matrix tablets of batches 
F1-F9 
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The drug release kinetics ware determined by DD solver disso 1 
software. The first order model was best fitted for all nine 
formulations as it showed maximum R2 
Statistical analysis of percent drug release at 10 h (Y
value. The values were in 
range of 0.9719 to 0.9966. 
1) the Model F-
value of 1901.08 implied that the model was significant. P value was 
found to be 0.0001, which indicated that model terms were 
significant. The coefficients of the variable terms in the polynomial 
equation for response Y1
%
 (Eq.3) indicated that sintering time, which 
was inversely related to drug release at 10 h had a more prominent 
effect than polymer concentration. 
rel 10 h =+86.82-1.37X1-6.30X2-1.66X1X2+0.046X12-1.78X2 2. 
(R2
Response surface plot of drug release at 10 h, the relationship 
between the variables at different levels and response was further 
elucidated by constructing 3-D response surface plots. The effects of 
X
=0.9997) Eq. 3 
1 and X2 
 
on response variables are shown in (fig. 4). Increase in EL-
100 and decrease in C. wax resulted in retardation of drug release. 
Similar effect was obtained with sintering time. 
 
Fig. 4: Response surface plot for %rel10 h 
 
Contact angle 
The effect of sintering on the wettability of the tablet surfaces was 
established by taking the photographs of the tablet. On the tablet 
surface, drop of purified water containing amaranth red was placed 
to measure contact angle. The contact angle of sintered tablet was 
greater than that of unsintered tablet, as shown in fig. 5. This clearly 
indicated that sintering decreases the wettability of tablet surfaces. 
The contact angle from batch F1 to F9 ranged from 43 to 67 ˚ (table 2).  
 
 
Fig. 5: Photo images showing contact angle of water with a) 
unsintered tablet and b) sintered tablet of F9 batch 
 
The wettability of tablet surface can be indicated by contact angle. It 
is an important physical property that profoundly impacts the 
release of the drug especially from a hydrophobic matrix. The 
surface of the tablets made from wet granulation consists of a 
heterogeneous mixture of the ingredients of the tablet. After 
sintering, the hydrophobic polymer can be considered to be more 
uniformly dispersed on tablet surface. It led to an increase in the 
contact angle of the tablet surface which was evidenced by the 
higher contact angle and lower wettability [7]. When tablets were 
exposed to temperatures over the melting point of the incorporated 
polymer, the polymer present in liquid state will move through the 
matrix of the tablet and get filled between the pores of the matrix 
without affecting the overall shape of the tablet. This coating of the 
drug particles is generally referred to as in situ micro-coating [27]. 
Statistical analysis of contact angle (Y2
The polynomial equation (4) for response Y
) the F-value of 1573.80 and P 
value was found to be 0.0001, which indicated that the quadratic 
model was significant. 
2 (contact angle) showed 
that sintering time had a more pronounce effect on contact angle 
than polymer concentration. The negative and low coefficients of the 
interaction term (X1 and X2
Response surface plot of contact angle, the relationship between the 
variables at different levels and response was further elucidated by 
constructing 3-D response surface plots. The effects of X1 and X2 on 
response variables were shown in (fig. 6). An increase in contact 
angle with increase in X1 and X2 factors was observed. 
) indicated an insignificant. 
Contact angle = +57.89 + 3.83X1 + 8.17X2 − 2.25X1X2 − 0.83X12
+ 0.17X22. (R2 = 0.9996). Eq. 4 
 
 
Fig. 6: Response surface plot for contact angle 
 
Porosity  
Tablet porosity is regarded as a measure of the tableting process. 
Variations in tablet porosity reflect various aspects of tablet 
compression performance. It is also related to tablet disintegration 
and dissolution [29]. The porosity of all batches was in the range of 
0.1288 to 0.1916. The rate of drug release was found to be inversely 
related to sintering time of matrix structure. Such increase in 
sintering time results in a decreased drug release rate because 
sintering is affected by porosity and mechanical strength of matrix 
tablet. Sintering time causes a increased tortuosity of the path of the 
drug [30]. The porosity of all batches F1-F9 as shown in (table no. 2.) 
Statistical analysis of porosity (Y3), The F-value 27.19 implies that 
the model was significant. P value was found to be 0.0106, which 
indicated that the quadratic model terms are significant. The 
negative and high value of coefficient of factor X1 (polymer 
concentration) in the polynomial equation 5 for response Y3 
(porosity) is indicative of a dominant role of both polymers in the 
particle rearrangement process during sintering. Though sintering 
time itself did not play a defining role in this response as evident 
from the low coefficient for X2, the high coefficient for the term X1X2 
portends a strong interaction between the two independent 
variables. The melting point of C. wax is reported to be between 78-
88° C [31] whereas of EL-100, it is>130° C [32]. Thus we understand 
that the sintering temperature of 80° C causes complete fusion of C. 
wax and EL-100 may just soften at this temperature. The 
densification of the matrix structure may be brought about by the 
action of capillary pressure caused by collapse of melt bridges 
between particles and by rearrangement of particles sliding over 
each other [33]. 
Porosity = +0.2308 − 2. 011X1 − 0.047X2 − 8.37X1X2 + 4.02 X12
+ 0.020X22. (R2 = 0.9784) Eq. 5 
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Response surface plot of porosity, the relationship between the 
variables at different levels and response was further elucidated by 
constructing 3-D response surface plots. The effects of X1 and X2 on 
response variables were shown in (fig. 7). A decreases porosity with 
increase in X1 and X2 factors.  
 
Fig. 7: Response surface plot for porosity 
 
Validation of optimizedmodel 
Validation of optimized model based on acceptance criteria and 
desirability factor Design Expert V 9.1 software suggested three 
optimum formulations of which one was selected based on the 
desirability values. The optimized formulation had polymer 
composition of 2:1 of EL-100 and C. wax with sintering time of 3h. 
The optimized formulation which was further subjected to in vivo 
studies. The experimental values of the responses matched the 
predicted values with a percent error in the range of 0.54-0.98. 
In vivo pharmacokinetic study 
In vivo pharmacokinetic study was performed in Wistar rats. Various 
pharmacokinetic parameters like Cmax (maximum concentration) 
and Tmax (time to reach maximum concentration) were directly 
obtained from the plasma concentration time curve (fig. 8). Tmax for 
matrix tablets and pure drug was found to be 8h and 1h with Cmax 
0.209µg/ml and 0.172µg/ml, respectively. The elimination constant 
(Kel) for drug in the matrix tablet was found to be 0.096/h while for 
the pure drug it was found to be 0.469/h. Based on the elimination 
constant, the biological half life was computed and was found to be 
7.16 h for the matrix tablet and 1.47 h for the pure drug. An increase 
of about 4.8 times was evident in the half life of drug in matrix tablet 
in comparison to the pure drug points to the increased residence 
time of drug in biological system. The AUC0-10 h of optimized tablet 
and plain drug was found to be 1.561 h. µg/ml and 0.481 h. µg/ml 
respectively. After oral administration, ITO undergoes rapid and 
extensive absorption, reaching peak plasma concentration in less 
than an hour and is eliminated via kidneys with an elimination half 
life of 6 h [34]. The sintered matrix tablets displayed a remarkable 
increase in bioavailability due to prolonged plasma residence as 
evident from the pharmacokinetic parameters. Thus we may 
conclude that effectively the dosing frequency can be reduced. 
 
Fig. 8: In vivo drug release profile of optimum formulation and 
pure drug ITO of matrix tablets 
Stability study  
Stability studies of optimum formulation revealed no significant 
changes in the physical parameters when stored at temperature and 
humidity conditions of 40°C/75% RH and at room temperature. No 
significant reduction in the content of the active drug was observed 
over a period of one month. 
CONCLUSION 
The present study involved prepared of sustained release matrix 
tablets of ITO using hydrophobic polymers and study of sintering 
technique in modulating drug release. Carnauba wax and Eudragit L 
100 were used as release retarding polymers. A 32
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optimization 
design was applied so as to achieve tablets with optimum drug 
release. Drug release mechanism was found to be diffusion-erosion 
because of polymer-wax combination. Optimization batches were 
studied for porosity, contact angle and tensile strength so as to 
understand effect of sintering on abovementioned properties. 
Decreased wettability and porosity along with increase in contact 
angle was evident for sintered tablets. These changes induced 
retardation in drug release. In vivo studies of optimized batch revealed 
4.8 times increase in t1/2 and sustained release of drug upto 10 h. 
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